Comparing a new docetaxel with standard docetaxel for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new docetaxel medication called HB1801 against the standard docetaxel (Taxotere) in people with advanced breast cancer. The goal is to see if HB1801 works just as well with similar or better side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that has spread or cannot be removed by surgery, and your doctor says docetaxel alone is a good treatment option.
- You have at least one tumor that can be measured on scans, and it has not been treated with radiation or has grown since radiation.
- You are at least 18 years old and your overall health is good enough for daily activities (ECOG score 0 or 1).
- Your major organs (like liver, kidneys, bone marrow) are working well, based on blood tests within the last week.
- You have not had docetaxel before for advanced breast cancer, and you do not have untreated or growing brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (HB1801, docetaxel, trastuzumab, and pertuzumab) for people with HER2-positive breast cancer that has spread or come back and cannot be removed by surgery. It is for those who have not yet received chemotherapy or HER2-targeted therapy for advanced disease.
This trial tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer that does not have an EGFR mutation and has stopped responding to previous treatments. The goal is to see which treatment works better.
This trial is testing a new form of the chemotherapy drug docetaxel (called albumin-bound docetaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this version of the drug works better or has fewer side effects.
This Phase 1/2 study tests a new oral drug (BLEX 404) together with docetaxel to see how safe it is and how well it works for people with advanced or metastatic triple-negative breast cancer. If you qualify, you would receive docetaxel by plan and also take BLEX 404 by mouth each day.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.